In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report), with a price target of $44.00. The company’s shares closed yesterday at $12.17.
Ramakanth covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Vericel, and ImmunoGen. According to TipRanks, Ramakanth has an average return of -19.5% and a 23.02% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for iTeos Therapeutics with a $44.00 average price target.
See the top stocks recommended by analysts >>
Based on iTeos Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $343 thousand and a GAAP net loss of $15.55 million. In comparison, last year the company earned a revenue of $41.72 million and had a net profit of $5.63 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Read More on ITOS:
